Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 14/20 | 0.60 |
| ▸ | CA1 | P00915 | 13/20 | 0.60 |
| ▸ | CA9 | Q16790 | 5/20 | 0.60 |
| ▸ | CA12 | O43570 | 3/20 | 0.60 |
| ▸ | CA6 | P23280 | 1/20 | 0.60 |
| ▸ | CA5A | P35218 | 1/20 | 0.60 |
| ▸ | CA7 | P43166 | 1/20 | 0.60 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.60 |
| ▸ | PTGES2 | Q9H7Z7 | 5/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7354878 | 0.85 | CA2 (0.59) | CA2CA1CA9CA12CA6 | |
| SCHEMBL7991708 | 0.82 | CA2 (0.56) | CA2CA1CA9CA12CA6 | |
| SCHEMBL3811394 | 0.81 | L3MBTL1 (0.60) | CA2CA1CA9CA12CA6 | |
| SCHEMBL4726651 | 0.81 | TTR (0.42) | CA2CA1CA9CA12 | |
| SCHEMBL25465864 | 0.80 | CA2 (0.55) | CA2CA1CA9CA12CA6 | |
| SCHEMBL22499523 | 0.80 | L3MBTL1 (0.63) | CA2CA1CA9CA12CA6 | |
| SCHEMBL3813975 | 0.80 | L3MBTL1 (0.63) | CA2CA1CA9CA12CA6 | |
| SCHEMBL20150147 | 0.79 | CA2 (0.60) | CA2CA1CA9CA12CA6 | |
| SCHEMBL4711064 | 0.79 | PTGES2 (0.64) | CA2CA1CA9CA12CA6 | |
| SCHEMBL28984186 | 0.78 | PTGES2 (0.58) | CA2CA1CA9CA12CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4229048-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | The Broad Institute, Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| WO-2022081807-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | THE BROAD INSTITUTE, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| EP-2238119-B1 | Quinazolines and related heterocyclic compounds, and their therapeutic use | VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS WETENSCHAPPELIJK ONDERZOEK EN PATIËNTENZORG (NL) | 2015-11-25 | — | — | EP | disclosed |
| US-8530486-B2 | Quinazolines and related heterocyclic compounds, and their therapeutic use | VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS, WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG (NL) | 2013-09-10 | — | — | US | disclosed |
| US-20100298322-A1 | Quinazolines and Related Heterocyclic Compounds, and Their Therapeutic Use | VERENIGING VOOR CHRISTELIJK, WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG (NL) | 2010-11-25 | — | — | US | disclosed |
| EP-2077263-A1 | Quinazolines and related heterocyclic compounds and their therapeutic use | Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg (NL) | 2009-07-08 | — | — | EP | disclosed |
| CN-1079398-C | Substituted arylsulfonylamino (thio) carbonyl-triazolin (thi) ones as herbicides | BAYER AG (DE) | 2002-02-20 | — | — | CN | disclosed |
| US-6200934-B1 | FOR COMBATING UNWANTED VEGETATION | BAYER AKTIENGESELLSCHAFT (DE) | 2001-03-13 | — | — | US | disclosed |
| CN-1218468-A | Substituted arylsulfonylamino (thio) carbonyl-triazolin (thi) ones as herbicides | BAYER AG (DE) | 1999-06-02 | — | — | CN | disclosed |
| EP-0888342-A1 | SUBSTITUTED ARYL SULPHONYL AMINO(THIO)CARBONYL-TRIAZOLIN(THI)ONES AS HERBICIDES | BAYER AG (DE) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997032876-A1 | SUBSTITUTED ARYL SULPHONYL AMINO(THIO)CARBONYL-TRIAZOLIN(THI)ONES AS HERBICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1997-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298322-A1 | Quinazolines and Related Heterocyclic Compounds, and Their Therapeutic Use | RXFP3, RXFP1, NR1I3 | CA2 879/4885CA1 1433/4885CA9 861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.